Recombinant therapeutic antibodies have become first-line treatments for a broad spectrum of human diseases, with Chinese hamster ovary (CHO) cells serving as the predominant mammalian host for industrial-scale production. Within CHO-based expression systems, vector design plays a critical role in determining recombinant antibody expression titers, product quality attributes (CQAs), and the efficiency of cell line development. As such, optimizing expression vectors can help accelerate the translation of antibody candidates from early-stage research to commercial biomanufacturing.

Despite the maturity of CHO-based production platforms, conventional expression systems continue to present opportunities to improve productivity and expression stability. Expression vector engineering is therefore a key lever in cell line development, with the potential to increase target protein titers without compromising product quality. In this whitepaper, Altruist Biologics presents an optimized promoter-engineering strategy designed to enhance recombinant protein productivity and mitigate expression decline in CHO clones.